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Introduction
Many autoantibodies, directed against a variety of
autoantigens, can be detected in the serum of rheumatoid
arthritis (RA) patients. Most of these autoantibodies
(reviewed in [1,2]), are also found in patients with other
diseases and are therefore not specific for RA. Even the
well known rheumatoid factor (RF) antibodies, directed
against the Fc part of IgG (reviewed in [3]), are not very
specific for RA [4,5]. Nevertheless, RF still is the most
commonly used serological marker for RA. Antibodies
directed to the Sa antigen have a much higher specificity
for RA. (This autoimmune system was first described
using the serum of an RA patient whose name began with
‘Sa’.) The antibodies target a doublet of protein bands of
approximately 50 kDa on western blots of extracts from
normal human placenta, spleen, and rheumatoid synovial
tissue [6].
In a recent review [7], the Sa antigen was suggested to be
identical to citrullinated vimentin, but data to support that
statement were not given at that time. In this report, we
provide such data and show that the Sa antigen is indeed
citrullinated vimentin. We show that anti-Sa antibodies
target citrullinated epitopes and not unmodified vimentin,
which makes them a member of the family of antibodies
directed to citrullinated proteins (reviewed in [8]).
Because citrulline, the antigenic determinant for these
autoantibodies, is a nonstandard amino acid, it is not
incorporated into proteins during translation. It can,
however, be generated post-translationally by enzymatic
CCP = cyclic citrullinated peptide; EGTA = ethylene glycol bis(β-aminoethylether) N,N’-tetraacetic acid; IEF = isoelectric focusing; IP = immuno-
precipitation; IPB = immunoprecipitation buffer; IPB–SDS = IPB containing 0.1% SDS; MC = modified citrulline; NP-40 = Nonidet P40; PAD =
peptidylarginine deiminase; PBS = phosphate-buffered saline; pI = isoelectric point; RA = rheumatoid arthritis; RF = rheumatoid factor; SEM = stan-
dard error of the mean; Tris = tris(hydroxymethyl)aminomethane.
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Abstract
Antibodies directed to the Sa antigen are highly specific for
rheumatoid arthritis (RA) and can be detected in approximately
40% of RA sera. The antigen, a doublet of protein bands of
about 50 kDa, is present in placenta and in RA synovial tissue.
Although it has been stated that the Sa antigen is citrullinated
vimentin, experimental proof for this claim has never been
published. In this study, we investigated the precise nature of
the antigen. Peptide sequences that were obtained from highly
purified Sa antigen were unique to vimentin. Recombinant
vimentin, however, was not recognized by anti-Sa reference
sera. In vivo, vimentin is subjected to various post-translational
modifications, including citrullination. Since antibodies to
citrullinated proteins are known to be highly specific for RA, we
investigated whether Sa is citrullinated and found that Sa
indeed is citrullinated vimentin. Anti-Sa antibodies thus belong
to the family of anticitrullinated protein/peptide antibodies. The
presence of the Sa antigen in RA synovial tissue, and the
recent observation that vimentin is citrullinated in dying human
macrophages, make citrullinated vimentin an interesting
candidate autoantigen in RA and may provide new insights into
the potential role of citrullinated synovial antigens and the
antibodies directed to them in the pathophysiology of RA.
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citrullination (deimination) of arginine residues. This conver-
sion is catalyzed by the enzyme peptidylarginine deiminase
(PAD, EC 3.5.3.15; reviewed in [9]). Because antibodies to
citrullinated proteins are very specific for RA, are detectable
very early in the disease, sometimes even during the preclin-
ical phase of RA [10,11], and are able to predict clinical
disease outcome [12–14], it is likely that these antibodies
will become progressively more valuable for the clinician.
We discuss the new perspective provided by our observa-
tion that Sa is citrullinated vimentin on the potential role of
citrullinated antigens and the antibodies directed to them
in RA pathophysiology.
Materials and methods
Patient sera and antibodies
In this study, we used 87 serum samples from patients
attending the Rheumatic Diseases Unit, Faculté de Medi-
cine, Université de Sherbrooke, Sherbrooke, QC, Canada.
Sixty-one sera were from RA patients satisfying the 1987
American Rheumatism Association criteria for the classifi-
cation of RA [15]: of these, 46 were anti-Sa-positive and
15, anti-Sa-negative. The 26 non-RA sera (8 osteoarthritis
patients, 14 systemic lupus erythematosus patients, 2
psoriatic arthritis patients, and 2 healthy individuals) were
all anti-SA negative. Experiments were approved by the
the ethics committee of the Université de Sherbrooke.
Rabbit antibodies directed against chemically modified cit-
rulline (anti-MC) were described previously [16,17]. Mouse
monoclonal antibodies (RV202) [18] and affinity-purified
rabbit polyclonal antibodies against vimentin were a kind
gift of Dr F Ramaekers (Maastricht, The Netherlands).
Preparation of placental Sa antigen
Semipurified placental extracts were prepared as
described previously [6,19]. Briefly, fresh human placenta
was homogenized in a low-salt Tris buffer (50 mM
Tris–HCl (pH 7.4), 120 mM NaCl, 0.02% NaN3, 1 mM
dithiothreitol, 1.5 mM phenylmethylsulfonyl fluoride (PMSF),
and 0.5 µg/ml each of chemostatin, leupeptin, antipain,
and pepstatin). The soluble fraction was separated by
anion-exchange chromatography. Sa proteins were eluted
with 300 mM of NaCl and subsequently desalted and
lyophilized for storage at –80°C.
Characterization of placental Sa antigen
To prepare Sa for amino acid sequencing, a three-step
purification procedure was performed essentially as
described by Liang and colleagues [20]. In the first step,
1 mg of the semipurified Sa (prepared as described above)
was resolved on a preparative 10% SDS–polyacrylamide
gel. Vertical strips were cut from each side of the gel and
were blotted onto nitrocellulose membrane. The blotted
strips were incubated with anti-Sa reference serum and
served to determine the exact position of the Sa bands.
In the second step of the procedure, the Sa-rich horizontal
strip was cut out of the preparative gel and washed exten-
sively in a freshly prepared, filtered and prewarmed (37°C)
wash solution (2 mM Tris–HCl [pH 8.0], 8 M deionized urea,
and 1% Nonidet P40 [NP-40]). The washed gel strip was
then loaded on an isoelectric focusing (IEF) gel (6 M urea,
1% NP-40, 6% acrylamide [39:1], 2% carrier ampholytes
[BioRad, Hercules, CA, USA] [pH range 3–10] and
0.067% riboflavin). IEF was performed as described by
Bouffard and colleagues [21]. IEF standards for pH range
3.6–6.6 (Sigma, St Louis, MO, USA) were used to esti-
mate the pI of the proteins. Immediately after migration, the
gel was fixed in 20% trichloroacetic acid (TCA) for 20 min
and then colored with Coomassie brilliant blue. Each indi-
vidual band was cut out and frozen at –20°C.
The third step of the procedure was to load excised bands
on a second preparative 10% SDS–polyacrylamide gel.
Each band from the IEF gel was divided over two lanes: one
was used for western blotting with anti-Sa reference serum
to determine the exact position of the Sa antigen, and the
other was stained with Coomassie brilliant blue. The bands
that matched the Sa antigen were excised from the
Coomassie-stained gel and washed twice with 50% ace-
tonitrile before being frozen and sent for microsequencing
to the Harvard microchemistry facility (Harvard University,
Cambridge, MA, USA) [22]. Peptides, generated by in-gel
digestion with trypsin, were separated by liquid chromatog-
raphy followed by double mass spectrometry (LC/MS/MS)
and finally sequenced by Edman degradation. The obtained
peptide sequences were used to identify the purified Sa
antigen using the US National Center for Biotechnology
Information (NCBI) nonredundant protein database.
Detection of autoantibodies
The presence of anti-Sa antibodies was determined by
immunoblotting as described previously [6,19]. Briefly,
semipurified Sa was loaded on 15% SDS–polyacrylamide
slab gels (0.1–0.2 mg total protein per centimeter of gel
width). After migration, proteins were blotted onto nitro-
cellulose membranes. Sera were diluted 1:40 and tested
for IgG anti-Sa. Immunoblots were scored independently
by two individuals.
Anti-CCP (cyclic citrullinated peptide) autoantibodies
were detected using the Rapscan RA mk2 kit (CCP2;
Euro-Diagnostica, Arnhem, The Netherlands) in accor-
dance with the instructions of the manufacturer.
Immunoprecipitation
Immunoprecipitations (IPs) were performed essentially as
described elsewhere [23]. Briefly, 2.5 mg of semipurified
Sa was dissolved by heating to 95°C for 1 min in 250 µl
buffer containing 20 mM Tris–HCl (pH 7.4), 20 mM ethyl-
ene glycol bis(β-aminoethylether) N,N′-tetraacetic acid
(EGTA), 1 mM dithioerythritol, and 2% SDS. Insoluble pro-Arthritis Research & Therapy    Vol 6 No 2 Vossenaar et al.
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teins were removed by centrifugation for 5 min at 13,000 g.
The supernatant was diluted with IP buffer (IPB: 50 mM
Tris–HCl (pH 7.2), 150 mM NaCl, 0.25% sodium deoxy-
cholate, 1% Triton X-100, and Complete protease
inhibitor cocktail [Roche Diagnostics, Mannheim,
Germany]) to a final concentration of 0.1% SDS. The
diluted solution was centrifuged for another 5 min at
13,000 g to remove insoluble proteins. Protein G agarose
beads (150 µl 50% slurry) were washed three times with
IPB–SDS (IPB containing 0.1% SDS). RV202 mono-
clonal antivimentin antibodies (150 µl) were incubated
with the beads in IPB–SDS for 4 hours at room tempera-
ture. After removal of unbound antibody by three washes
with IPB–SDS, 500 µg Sa (1 ml of diluted solution) was
incubated with the beads overnight at 4°C. After extensive
washing (three washes with IPB–SDS, one wash with
IPB–SDS supplemented with 100 mM KCl, and a last
wash with IPB–SDS), bound proteins were eluted by
boiling in SDS–sample buffer (250 mM Tris–HCl [pH 6.8],
2% SDS, 5% β-mercaptoethanol). The immunoprecipitate
was divided over three 13% SDS–polyacrylamide gels
and transferred to Hybond-C Extra membranes (Amer-
sham Biosciences, Little Chalfont, Buckinghamshire, UK).
The blots were stained with either anti-MC antibodies,
anti-Sa reference serum, or polyclonal antivimentin anti-
bodies, as described below. As a negative control, an IP
was performed with an isotype-matched, unrelated control
antibody (4G3 directed to U2 snRNP B′′ protein [24]).
Citrullination of vimentin
Human recombinant vimentin (Research Diagnostics Inc,
Flanders, NJ, USA) was citrullinated in vitro by rabbit
muscle PAD (Sigma; 40 U of PAD per milligram of
vimentin) for 3 hours at 55°C in a buffer containing 0.1 M
Tris–HCl (pH 7.6), 10 mM CaCl2, and 5 mM dithioerythri-
tol. The reaction was stopped by adding EGTA (pH 8.0) to
a final concentration of 50 mM. The extent of the citrullina-
tion was estimated by immunoblotting with anti-MC anti-
bodies (described below).
Western blotting
Blots were incubated in blocking buffer (PBS containing
5% nonfat dried milk and 0.1% NP-40) for 1 hour at room
temperature and 1–3 hours with the antibody of interest
diluted in blocking buffer. After washing the blot with
blocking buffer, bound antibodies were detected by incu-
bation with horseradish-peroxidase-conjugated secondary
antibodies, followed by chemiluminescence. For the
detection of citrullinated proteins, blots were chemically
treated before immunostaining with anti-MC antibodies, as
described previously [16].
Results
Characterization of the Sa antigen
Antibodies directed to Sa are highly specific for RA. To
investigate the identity of the Sa antigen, we performed a
multistep purification procedure as described in Materials
and methods. The accuracy of each step of the procedure
was monitored by immunoblotting using anti-Sa reference
serum. The result of final purification is shown in Fig. 1,
where the estimated molecular weight of Sa is ~50 kDa
and its pI is 5.0. Two peptide sequences were obtained
(indicated in Fig. 2; peptide 72–86 was obtained twice)
that uniquely matched the sequence of vimentin. The cal-
culated molecular weight (54 kDa) and pI (5.1) of vimentin
closely resemble those of Sa.
Discordance between anti-Sa and anti-unmodified
vimentin but strong concordance between anti-Sa and
anti-CCP status
To confirm that Sa is vimentin, we prepared immunoblots
containing human recombinant vimentin. Antivimentin
reactivity was observed at lower serum dilutions in only a
subset of the patients, irrespective of their anti-Sa or
disease status (results not shown). Concordance between
reactivity to Sa and reactivity to vimentin was thus not
observed. Vimentin is known to undergo several post-
translational modifications, including phosphorylation and
citrullination [25,26]. Since antibodies directed to citrulli-
nated proteins are very specific for RA [1], we investigated
whether anti-Sa sera are reactive with citrullinated epi-
topes. The vast majority (96%) of anti-Sa-positive RA
patients tested positive for anti-CCP2, using the CCP2
test kit, as did a substantial proportion (60%) of the anti-
Sa-negative RA patients. Anti-SA-negative RA sera had
significantly lower anti-CCP2 titers than anti-Sa-positive
sera (Fig. 3). These results suggest that anti-Sa sera
contain antibodies that are reactive with citrullinated epi-
topes.
Figure 1
Purification of placental Sa antigen. The antigen was purified by anion-
exchange chromatography from extracts of placenta and subsequently
purified by two-dimensional gel electrophoresis according to a three-
step procedure described by Liang and colleagues [20]. First, proteins
were separated by molecular weight, then proteins of appropriate
molecular weight were separated by isoelectric focusing (IEF), and
finally proteins with appropriate pI were separated once more by
molecular weight. Each step of the procedure was monitored by
western blotting with an anti-Sa reference serum. Shown here is the
final gel, which was stained with Coomassie brilliant blue. The double
band in lane 2 is the Sa antigen that was cut out and used for
microsequencing. Each lane represents a portion of the IEF gel
(approximate pI is listed above each lane).The placental Sa antigen is citrullinated vimentin
To investigate whether Sa is citrullinated vimentin, we used
a method to detect citrullinated proteins in cell extracts or
fixed cells. In this method, the citrulline sidechain is specifi-
cally modified by chemical treatment into complex struc-
tures that are so bulky that the influence of flanking amino
acids for epitope recognition becomes negligible
[16,17,26–28]. Citrullinated proteins are detected (after
chemical treatment) by antibodies specifically targeting
those modified citrullines (anti-MC). Noncitrullinated pro-
teins cannot be modified by the chemical treatment and are
thus not recognized by the specific antibodies.
We prepared three identical immunoblots (Fig. 4) contain-
ing semipurified placental Sa antigen, human recombinant
vimentin, and human recombinant vimentin that had been
citrullinated in vitro. The Sa antigen was recognized by
anti-Sa reference serum, by antivimentin antibodies, and
by anti-MC antibodies (lanes 1, 4, and 7, respectively),
indicating that the antigen is indeed citrullinated vimentin.
Furthermore, citrullinated vimentin was recognized by the
anti-Sa serum, whereas unmodified vimentin was not
(lanes 3 and 2, respectively), indicating that the presence
of citrulline residues is essential for the autoantigenicity of
vimentin. The differences in the positions of the bands can
be attributed to the extent of post-translational processing.
Data in the literature show decreased mobilities with
increased citrullination of filaggrin and trichohyalin [29].
Furthermore, the increased mobility of the Sa antigen in
comparison with the recombinant proteins may be the
result of partial proteolytic processing, as this has been
described for keratins in the cornified layer of the epider-
mis [30–32].
In addition, we performed IP experiments. Vimentin was
immunoprecipitated from the semipurified Sa preparation
with monoclonal antivimentin antibody. Immunoprecipi-
tated vimentin was stained both by anti-MC antibodies
and by anti-Sa reference serum (Fig. 5), confirming that
citrullinated vimentin is the antigenic Sa protein.
Discussion
Autoantibodies against the placental Sa antigen were
described for the first time over a decade ago [6]. Since
then, this autoimmune system has proven to be highly spe-
cific for RA in populations of patients from Europe, America,
and Asia [7]. The mean sensitivity of the assay is 37%
(range 21–43%) with 98% specificity (range 92–100%)
and a positive predictive value between 95 and 99% [7].
Although it was previously suggested that Sa might be
identical to citrullinated vimentin [7], evidence for this
statement has not been published. This had led to confu-
sion in the literature regarding the exact nature of the
antigen. Indeed, it was proposed that Sa could be identi-
cal to the glycolytic enzyme α-enolase [33] or to calpa-
statin [34], the natural inhibitor of calpains. Both types of
autoantibody, however, turned out to be independent
autoimmune systems, associated with but not specific for
RA [35,36]. Other workers have claimed that apolipopro-
tein-A-1-binding protein could be (part of) the Sa antigen
[37]. More recently, autoantibodies not specific for RA
and directed to a 68-kDa placental protein were reported
[38]. Nevertheless, the authors of that study still chose,
inappropriately, to label this antigen Sa. We thus deemed
it important to report the experimental evidence relating to
the exact nature of the Sa antigen.
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Figure 3
Comparison of anti-CCP titers in Sa+ and Sa– patients. To investigate
a possible relationship between anti-Sa and anti-CCP autoantibodies,
we compared anti-CCP2 antibody titers in 46 anti-Sa-positive
rheumatoid arthritis (RA) sera, 15 anti-Sa-negative RA sera, and 26
control sera, using the CCP2 test kit. Ninety-six percent of anti-Sa-
positive RA patients, 60% of Sa-negative RA-patients, and none of the
control patients was positive for anti-CCP2. Anti-Sa-positive RA sera
had a significantly higher anti-CCP titer (852 ± 96 U; mean ± SEM)
than anti-SA-negative sera (263 ± 110 U) (P < 0.0005;
Mann–Whitney test). None of the control sera tested positive in either
of the two assays (12 ± 0.4 U).
Figure 2
Amino acid sequence of vimentin with Sa microsequences and
sequence of human vimentin (Swiss-Prot database number P08670).
Two distinct peptides that were obtained by microsequencing are
indicated in grey. Peptide 72–86 was obtained twice, VD84–85 was
ambiguous in one of the peptides, and R78 could not be sequenced in
both peptides. All arginines are given in capital and bold, because they
can potentially be modified to citrulline by peptidylarginine deiminase.We obtained several peptide sequences from highly puri-
fied preparations of Sa antigen that were unique to the
intermediate filament protein vimentin. Autoantibodies
directed to vimentin were described many years ago in RA
[39] as well as in other autoimmune diseases [39,40], in
infectious diseases [41,42], and even in healthy individu-
als [43]. Those antivimentin autoantibodies, which are
mainly of the IgM class, are not specific for RA. In con-
trast, anti-Sa antibodies are highly specific for RA and are
predominantly IgG [6].
Here, using recombinant human vimentin, we found IgG
antivimentin antibodies in only a few sera. The antibodies
were only found in low titers, were not related to anti-Sa
positivity, and had no disease specificity. Thus we con-
clude that anti-Sa sera do not target native (unmodified)
vimentin.
Many known autoantibodies are directed against proteins
that become modified during cell death and in particular
during apoptosis (reviewed in [44,45]). These modifica-
tions include proteolytic cleavage by caspases or
granzyme B [46], transglutamination [47], (de)phosphory-
lation [48,49], and also citrullination [26,50]. When these
modified self proteins are inefficiently cleared, they may be
presented to the immune system and might be recognized
as ‘nonself’ [51]. If sufficient ‘danger signals’ are present
(as in an inflammatory environment), this can lead to an
immune response against the modified proteins [51,52].
Vimentin can be subjected to various post-translational
modifications that could be important for its autoantigenic-
ity. Those modifications are not present in the recombinant
vimentin, and this fact could readily explain why we did not
observe significant antivimentin reactivity in anti-Sa-posi-
tive patients.
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Figure 4
Placental Sa antigen is citrullinated vimentin. Three identical
immunoblots containing semipurified placental Sa antigen (100 µg;
lanes 1, 4, 7), human recombinant vimentin (Vim) (50 ng; lanes 2, 5, 8),
and human recombinant vimentin that had been citrullinated in vitro
(cit-Vim) (50 ng; lanes 3, 6, 9) were stained with either anti-Sa
reference serum (left panel), anti-modified citrulline (anti-MC)
antibodies (middle panel), or antivimentin (anti-Vim) antibodies (right
panel). Sa antigen is recognized both by anti-MC antibodies and by
anti-Vim antibodies (lanes 4 and 7, respectively), indicating that the
antigen is indeed citrullinated vimentin. Citrullinated vimentin was
recognized by the anti-Sa serum, whereas unmodified vimentin was not
(lanes 3 and 2, respectively), indicating that the presence of citrulline
residues is essential for the autoantigenicity of Sa. Molecular weight
markers are indicated on the left.
Figure 5
Antivimentin (anti-Vim) can immunoprecipitate Sa antigen from
placental extract. Vimentin was immunoprecipitated from semipurified
placental extract with monoclonal antibody RV202 (lanes 3).
Immunoprecipitated vimentin was stained by anti-modified citrulline
(anti-MC) antibodies (upper panel), anti-Sa serum (middle panel), or
polyclonal antivimentin (anti-Vim) antibodies (lower panel), indicating
that Sa is citrullinated vimentin. An immunoprecipitation (IP) with an
isotype-matched monoclonal control antibody 4G3 (lanes 4) served as
a negative control. Lanes 1 contain human recombinant vimentin
citrullinated in vitro (cit-Vim) (50 ng) as a positive control. Lanes 2
show 10% input . Molecular weight markers are indicated on the left.Intermediate filaments are a major component of the
cytoskeleton of eukaryotic cells. Together with the actin
microfilaments and microtubules, they form an integrated
network that is responsible for the mechanical integrity of
the cell and is critically involved in processes such as cell
division, motility, and plasticity. Although there are at least
five distinct classes of intermediate filament, cells of mes-
enchymal origin and most cells in culture contain interme-
diate filaments composed of vimentin. Vimentin
intermediate filaments are dynamic structures [53] and
their flexible organization is important for various cellular
processes [54]. The filaments are composed of homopoly-
mers of vimentin subunits [55]. The polymerization of the
free subunits into filaments is a reversible process, in
which phosphorylation is an important regulating factor;
free vimentin subunits are more heavily phosphorylated
(on their amino terminal head domain) than polymerized
vimentin [25,53]. Vimentin can also be citrullinated, which
means that some of its arginine residues are deiminated to
citrulline residues. This modification of vimentin has been
described as occurring in dying macrophages [26,28]. It
is known that citrullination of the amino terminal head
domain by PAD induces disassembly of the vimentin fila-
ments  in vitro [50]. Therefore, citrullination may be
involved in the disassembly of the vimentin cytoskeleton
during cell death, when the network of vimentin filaments
collapses into perinuclear aggregates. The phosphoryla-
tion and citrullination of vimentin may account for the small
differences between calculated and observed molecular
weight/pI values (53.6/5.1 vs ~50/5.0) and also for the
differences in gel mobility observed in Fig. 4. Larger varia-
tions in molecular weight/pI values of vimentin have been
reported elsewhere (66.9/5.6 and 48.6/4.6) [56].
The existence of citrullinated vimentin provided us with
new clues to the nature of the Sa antigen. Autoantibodies
directed to citrullinated proteins are highly specific for RA
(reviewed in [8]). Besides their high specificity, they share
more features with the anti-Sa antibodies. They can be
detected very early in the disease and can often predict
the clinical outcome of the disease [10,57,58]. Further-
more, both types of autoantibody correlate with the pres-
ence of HLA-DR shared epitope [58,59]. To investigate
whether anti-Sa sera are indeed directed against citrulli-
nated epitopes, we tested 87 sera of known anti-Sa status
in the anti-CCP2 assay. Our aim was not to compare the
two assays, since we did not test large numbers of ran-
domly selected patients, but to investigate the concor-
dance or lack of it between anti-Sa and anti-CCP antibody
status. Of the anti-Sa-positive RA sera, most were also
positive for anti-CCP. Of anti-SA-negative RA sera, a con-
siderable proportion was anti-CCP-positive, albeit at a
lower titer. The anti-CCP titers of anti-Sa-positive patients
were on average more than three times as high as those of
anti-Sa-negative RA patients. It thus appears that mainly
sera that are strongly positive for anti-CCP will score posi-
tive for anti-Sa. This observation is in agreement with the
difference in sensitivities of the two assays (70–80% for
anti-CCP2, 30–40% for anti-Sa) [7,8]. Other assays that
detect anticitrullinated protein antibodies by immunoblot-
ting (using filaggrin as the antigen) have sensitivities
(~40%) comparable with the sensitivity of the anti-Sa
assay [60–62].
The presence of antibodies to citrullinated proteins is cor-
related with a more severe disease outcome, especially
when high titers of the antibody are present (reviewed in
[8]). In an early RA cohort study, the presence of anti-Sa
antibodies appeared to be slightly more correlated with
erosive disease outcome than the presence of anti-CCP
[63], a finding that is in agreement with the idea that the
Sa antigen is recognized by patients with high titers of
anticitrullinated protein antibodies.
To actually prove that the placental Sa antigen is citrulli-
nated vimentin, we performed western blotting and IP
experiments. Sa was recognized by anti-MC antibodies,
showing that it does contain citrulline residues. Further-
more, anti-Sa serum was reactive with vimentin citrulli-
nated in vitro but not with unmodified vimentin, showing
that citrulline is essential for antigenicity. Finally, antigenic
Sa protein could be immunoprecipitated from semipurified
placental extracts by antivimentin antibodies, showing that
the antigenic citrulline residues are indeed carried by
vimentin. Taken together, our results show that the placen-
tal Sa antigen is citrullinated vimentin. Therefore, anti-Sa
antibodies belong to the expanding family of anticitrulli-
nated protein antibodies (reviewed in [8]), which includes
antiperinuclear factor [64], anti-‘keratin’ antibodies [65],
antifilaggrin antibodies [66,67], and anti-CCP antibodies
[68,69]. Their common antigenic determinant is the non-
standard amino acid citrulline; the name of the antibody is
simply determined by the antigen used to detect them.
Not every citrulline residue in a protein will provide a good
epitope, however, because the amino acids flanking the
citrulline residue are important for the presentation of the
antigenic citrulline residue. Therefore, proteins with a high
arginine content, such as filaggrin, fibrinogen, vimentin,
histones, or myelin basic protein, are more likely to contain
reactive epitopes upon citrullination than are proteins with
low arginine content, such as albumin [70]. In fact, most of
the  in vitro-citrullinated arginine-rich proteins mentioned
here have been used in diagnostic assays to detect the RA
specific anticitrullinated protein antibodies (filaggrin
[62,71], fibrinogen [72], myelin basic protein [70]).
Because each antigen and each test format (immunofluo-
rescence, immunoblot, or ELISA) will show different values
for sensitivity and specificity for RA, care should be taken in
using the proper nomenclature and standardization.
The commercially available anti-CCP2 test has a reported
sensitivity of almost 80% and a specificity of 98% [73,74].
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patients tested negative for anti-CCP. Vimentin contains
43 arginine residues (see Fig. 2). Each of them can poten-
tially be citrullinated by PAD, resulting in a large variety of
citrullinated epitopes. In contrast, in the anti-CCP2 test
only a few epitopes are presented. It had been previously
established that RA sera show a remarkable variety in the
reactivity pattern towards different citrulline-containing
peptides, indicating, as previously mentioned, that the
amino acids flanking the citrulline residue are important for
the antigenicity of the epitope and that anticitrullinated
protein reactivity is a strongly polyclonal response [68]. It
follows that anti-Sa-positive/anti-CCP-negative sera are
most likely directed to citrullinated epitopes that are
present only on the Sa antigen.
Conclusion
The placental Sa antigen specifically recognized by anti-
bodies in serum from RA patients has been identified as
citrullinated vimentin. Anti-Sa antibodies, therefore, belong
to the family of anticitrullinated protein antibodies. The Sa
antigen is present in the rheumatoid pannus [6]. We
recently observed that vimentin is citrullinated in dying
human macrophages [28]. Furthermore, it has been
reported that vimentin-derived citrullinated peptides were
able to bind to HLA-DR4 shared epitope much more effi-
ciently than noncitrullinated peptides [75]. These findings,
together with our identification of the Sa antigen, make cit-
rullinated vimentin an interesting candidate autoantigen in
RA and may provide new insights into the potential role of
citrullinated synovial antigens and the antibodies directed
to them in the pathophysiology of RA.
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